Genentech, a member of Roche Holding AG, has recently commenced construction on a cutting-edge manufacturing facility in Holly Springs, North Carolina. This significant $700 million project is part of Roche's substantial $50 billion investment in U.S. manufacturing, infrastructure, and R&D. The facility will focus on producing next-generation metabolic medicines, including treatments for obesity, and is expected to generate over 1,900 jobs. The site, strategically located in a biopharmaceutical innovation hub, is designed for high-volume, efficient, and sustainable production and is set to be operational by 2029. This development underscores Roche's commitment to delivering life-changing treatments to patients more efficiently and expanding its U.S. presence.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。